Abstract
Simple SummaryPost-polypectomy endoscopic surveillance is predominantly based on the size and number of polyps found at baseline. The utility of molecular markers for predicting the risk of metachronous advanced lesions remains poorly investigated. Patients with CpG island methylator phenotype (CIMP)+ polyps show a higher risk of developing advanced lesions at follow-up. This fact is independent of polyp size and other factors classically related to advanced lesion development. Addition of CIMP status improved the metachronous advanced colorectal lesion (MACL) risk estimation, especially the sensitivity. CIMP may be a useful marker for endoscopic surveillance after polypectomy.The utility of molecular markers for predicting the risk of metachronous advanced colorectal lesions (MACLs) remains poorly investigated. We examined the relationship between somatic hypermethylation in polyps at baseline and the risk of developing MACL. This retrospective cohort study included 281 consecutive patients with colonic polyps who were enrolled between 2007 and 2009 and followed-up until 2014. MACLs were defined as adenomas of ≥10 mm, high-grade dysplasia, or with a villous component; and serrated lesions of ≥10 mm or with dysplasia. In total, 595 polyps were removed at baseline colonoscopy and analyzed for pathological characteristics and CpG island methylator phenotype (CIMP) using the MS-MLPA (Methylation-Specific -- Multiplex Ligation-dependent Probe Amplification) technique. Forty-five patients (16.0%) showed at least one CIMP+ polyp. MACL risk was higher in patients with CIMP+ polyps (odds ratio (OR), 4.50; 95% CI, 1.78–11.4; p = 0.002). Patients with CIMP+ polyps also exhibited shorter time to MACL development (33.8 months vs. 50.1 months; p < 0.001), even with adjustment for polyp size and number (OR, 2.40; 95% CI, 1.33–4.34). Adding CIMP analysis improved the sensitivity (57.0% to 70.9%), negative predictive value (71.1% to 77.3%), and overall accuracy (49.8% to 52.0%) for MACL risk estimation. These results highlight that CIMP may be a useful marker for endoscopic surveillance.
Highlights
Colorectal cancer (CRC) is a major cause of cancer morbidity and death in developed countries
We aimed to evaluate whether the presence of CpG island methylator phenotype (CIMP)+ polyps in adenomatous and serrated lesions at baseline colonoscopy could predict metachronous advanced colorectal lesions (MACLs) risk at follow-up
The results of our study suggest that the CIMP status of polyps removed at baseline may be a predictor of future MACL development during follow-up
Summary
Colorectal cancer (CRC) is a major cause of cancer morbidity and death in developed countries. Patients who undergo removal of advanced adenomas or serrated polyps during colonoscopy carry an increased risk of developing metachronous lesions and, eventually, CRC. In the guidelines for surveillance after polyp excision, patients are stratified into risk groups mainly according to characteristics of the lesions found at the index colonoscopy [4]. The rationale behind such categorization is that the advanced neoplasia risk at follow-up colonoscopy depends on the number, size, and histology of polyps at baseline. Few studies have investigated the relationship between molecular markers and risk of developing metachronous neoplasia at follow-up. Studies applying the consensus molecular subtypes (CMSs) of CRC to polyps have indicated that certain genetic anomalies may be markers of future CRC risk [6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
